Trial Profile
A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ALT 801 (Primary) ; Gemcitabine
- Indications Bladder cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors Altor BioScience Corporation
- 07 Jan 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified January 2017).
- 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2018.
- 11 Apr 2016 Status changed from recruiting to active, no longer recruiting.